{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:26:14Z","timestamp":1783441574659,"version":"3.54.6"},"reference-count":22,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2022]]},"DOI":"10.1620\/tjem.2022.j071","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T22:22:49Z","timestamp":1661984569000},"page":"159-165","source":"Crossref","is-referenced-by-count":6,"title":["Cerebrospinal Fluid Interleukin-6 in Immune Checkpoint Inhibitor-Induced Autoimmune Meningoencephalitis"],"prefix":"10.1620","volume":"258","author":[{"given":"Takeshi","family":"Mizukami","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruaki","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotatsu","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Jikumaru","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Hanaoka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Akman-Demir, G., Tuzun, E., Icoz, S., Yesilot, N., Yentur, S.P., Kurtuncu, M., Mutlu, M. &amp; Saruhan-Direskeneli, G.(2008)  Interleukin-6 in neuro-Behcet\u2019s disease: association with disease subsets and long-term outcome.  <i>Cytokine<\/i>, 44, 373-376.","DOI":"10.1016\/j.cyto.2008.10.007"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bruna, J., Argyriou, A.A., Anastopoulou, G.G., Alemany, M., Nadal, E., Kalofonou, F., Piulats, J.M., Simo, M., Velasco, R. &amp; Kalofonos, H.P.(2020)  Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials.  <i>J. Peripher. Nerv. Syst<\/i>., 25, 171-177.","DOI":"10.1111\/jns.12371"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R. &amp; Carpentier, A.F.(2017)  Neurological adverse events associated with immune checkpoint inhibitors: review of the literature.  <i>Eur. J. Cancer<\/i>, 73, 1-8.","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Dubey, D., David, W.S., Reynolds, K.L., Chute, D.F., Clement, N.F., Cohen, J.V., Lawrence, D.P., Mooradian, M.J., Sullivan, R.J. &amp; Guidon, A.C.(2020)  Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum.  <i>Ann. Neurol<\/i>., 87, 659-669.","DOI":"10.1002\/ana.25708"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Eigentler, T.K., Hassel, J.C., Berking, C., Aberle, J., Bachmann, O., Grunwald, V., Kahler, K.C., Loquai, C., Reinmuth, N., Steins, M., Zimmer, L., Sendl, A. &amp; Gutzmer, R.(2016)  Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.  <i>Cancer Treat. Rev<\/i>., 45, 7-18.","DOI":"10.1016\/j.ctrv.2016.02.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Fujiwara, S., Mimura, N., Yoshimura, H., Fujimoto, D., Ito, M., Mori, R., Ito, J., Tomii, K., Kawamoto, M. &amp; Kohara, N.(2019)  Elevated adenosine deaminase levels in the cerebrospinal fluid in immune checkpoint inhibitor-induced autoimmune encephalitis.  <i>Intern. Med<\/i>., 58, 2871-2874.","DOI":"10.2169\/internalmedicine.2537-18"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Husain, B., Kirchberger, M.C., Erdmann, M., Schupferling, S., Abolhassani, A.R., Frohlich, W., Berking, C. &amp; Heinzerling, L.(2021)  Inflammatory markers in autoimmunity induced by checkpoint inhibitors.  <i>J. Cancer Res. Clin. Oncol<\/i>., 147, 1623-1630.","DOI":"10.1007\/s00432-021-03550-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Johnson, D.B., Nebhan, C.A., Moslehi, J.J. &amp; Balko, J.M.(2022)  Immune-checkpoint inhibitors: long-term implications of toxicity.  <i>Nat. Rev. Clin. Oncol<\/i>., 19, 254-267.","DOI":"10.1038\/s41571-022-00600-w"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P.F., Hill, A., Wagstaff, J., Carlino, M.S., Haanen, J.B.,  et al.(2015)  Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.  <i>N. Engl. J. Med<\/i>., 373, 23-34.","DOI":"10.1056\/NEJMoa1504030"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Ohno, N., Sugimoto, T., Giga, M., Naito, H., Kono, T. &amp; Nomura, E.(2021)  A case of meningoencephalitis and polyradiculoneuropathy induced by combination therapy with ipilimumab and nivolumab.  <i>Rinsho Shinkeigaku<\/i>, 61, 658-662.","DOI":"10.5692\/clinicalneurol.cn-001582"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Postow, M.A., Sidlow, R. &amp; Hellmann, M.D.(2018)  Immune-related adverse events associated with immune checkpoint blockade.  <i>N. Engl. J. Med<\/i>., 378, 158-168.","DOI":"10.1056\/NEJMra1703481"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., Flores-Chavez, A., Keegan, N., Khamashta, M.A., Lambotte, O., Mariette, X., Prat, A. &amp; Suarez-Almazor, M.E.(2020)  Immune-related adverse events of checkpoint inhibitors.  <i>Nat. Rev. Dis. Primers<\/i>, 6, 38.","DOI":"10.1038\/s41572-020-0160-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Ribas, A. &amp; Wolchok, J.D.(2018)  Cancer immunotherapy using checkpoint blockade.  <i>Science<\/i>, 359, 1350-1355.","DOI":"10.1126\/science.aar4060"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Sato, K., Mano, T., Iwata, A. &amp; Toda, T.(2019)  Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.  <i>J. Neurooncol<\/i>., 145, 1-9.","DOI":"10.1007\/s11060-019-03273-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Sznol, M., Ferrucci, P.F., Hogg, D., Atkins, M.B., Wolter, P., Guidoboni, M., Lebbe, C., Kirkwood, J.M., Schachter, J., Daniels, G.A., Hassel, J., Cebon, J., Gerritsen, W., Atkinson, V., Thomas, L.,  et al.(2017)  Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma.  <i>J. Clin. Oncol<\/i>., 35, 3815-3822.","DOI":"10.1200\/JCO.2016.72.1167"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Uzawa, A., Mori, M., Masuda, H., Ohtani, R., Uchida, T., Sawai, S. &amp; Kuwabara, S.(2017)  Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica.  <i>Clin. Chim. Acta<\/i>, 469, 144-149.","DOI":"10.1016\/j.cca.2017.03.006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Valpione, S., Pasquali, S., Campana, L.G., Piccin, L., Mocellin, S., Pigozzo, J. &amp; Chiarion-Sileni, V.(2018)  Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.  <i>J. Transl. Med.<\/i>, 16, 94.","DOI":"10.1186\/s12967-018-1467-x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Velasco, R., Villagran, M., Jove, M., Simo, M., Vilarino, N., Alemany, M., Palmero, R., Martinez-Villacampa, M.M., Nadal, E. &amp; Bruna, J.(2021)  Encephalitis induced by immune checkpoint inhibitors: a systematic review.  <i>JAMA Neurol<\/i>., 78, 864-873.","DOI":"10.1001\/jamaneurol.2021.0249"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Vogrig, A., Mu\u00f1iz-Castrillo, S., Joubert, B., Picard, G., Rogemond, V., Marchal, C., Chiappa, A.M., Chanson, E., Skowron, F., Leblanc, A., Ducray, F. &amp; Honnorat, J.(2020)  Central nervous system complications associated with immune checkpoint inhibitors.  <i>J. Neurol. Neurosurg. Psychiatry<\/i>, 91, 772-778.","DOI":"10.1136\/jnnp-2020-323055"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Wullschleger, A., Kapina, V., Molnarfi, N., Courvoisier, D.S., Seebach, J.D., Santiago-Raber, M.L., Hochstrasser, D.F. &amp; Lalive, P.H.(2013)  Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.  <i>PLoS One<\/i>, 8, e72399.","DOI":"10.1371\/journal.pone.0072399"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Xu, M., Nie, Y., Yang, Y., Lu, Y.T. &amp; Su, Q.(2019)  Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis.  <i>Neurologist<\/i>, 24, 75-83.","DOI":"10.1097\/NRL.0000000000000230"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Yamaguchi, Y., Nagasawa, H., Katagiri, Y. &amp; Wada, M.(2020)  Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.  <i>J. Med. Case Rep.<\/i>, 14, 88.","DOI":"10.1186\/s13256-020-02411-y"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/258\/2\/258_2022.J071\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T05:11:56Z","timestamp":1664601116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/258\/2\/258_2022.J071\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2022.j071","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"2022.J071"}}